Jun 08, 2023 / 03:00PM GMT
Akash Tewari - Jefferies & Co., Inc. - Analyst
Still good morning. All right, good morning, everyone. Day two of our Jefferies Healthcare Conference. I hope everyone's enjoying themselves. I have -- for those who don't know me, my name is Akash Tewari. I'm a pharma and biotech analyst here, and I have the pleasure of hosting Arvinas, which as of just in an AK this morning, published some new data on their AR degrader franchise, and this is certainly a part of your company that I think doesn't get enough attention right now, and I could critique myself. I don't think I've given it enough attention.
So maybe I'll hand it off to Ron to give some brief introductory remarks and go over some of the data.
Ron Peck - Arvinas, Inc. - Chief Medical Officer
Yeah. Certainly. Yeah. And just to say that John Houston, who's a CEO, will probably be walking in any minute, and yeah. So well -- and Ian Taylor will be joining us as well as a Chief Scientific Officer.
Yeah, so we're really excited to have this opportunity to disclose our initial data on 766,
Arvinas Inc at Jefferies Healthcare Conference Transcript
Jun 08, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers